基因组分析确定了肺癌亚型的基因修饰。
Genome analyses identify the genetic modification of lung cancer subtypes.
机构信息
Zhongshan Hospital Institute of Clinical Science, Fudan University, Shanghai Institute of Clinical Bioinformatics, Biomedical Research Center, Shanghai, China.
Zhongshan Hospital Institute of Clinical Science, Fudan University, Shanghai Institute of Clinical Bioinformatics, Biomedical Research Center, Shanghai, China.
出版信息
Semin Cancer Biol. 2017 Feb;42:20-30. doi: 10.1016/j.semcancer.2016.11.005. Epub 2016 Nov 11.
Lung cancer is a highly intricate and heterogeneous disease with genomic diversity in each subtype. Global analyses of gene expression and sequencing provided us new understanding of the genetic variation between small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC), including adenocarcinoma (ADC), and squamous cell carcinoma (SCC). The genetic variations of lung cancer subtypes in genomic studies were integrated and further analyzed using bioinformatics methods. The lung cancer subtypes share some genetic variations such as the dysfunction of tumor suppressor gene TP53, and also harbor specific variations of their own such as MET in ADC, FGFR1 and FGFR3 in SCC and MYC in SCLC. The activated pathway in lung ADC and SCC mainly focuses on MAPK and PI3K with different key genes of each, respectively, and the activated pathway of SCLC mainly focuses on JAK-STAT pathway. The diagnosis of lung cancer subtypes based on these genetic variations such as SNP was also evaluated. These results provide further insights into the different pathogenesis of lung cancer subtypes.
肺癌是一种高度复杂和异质性的疾病，每个亚型都存在基因组多样性。对基因表达和测序的全球分析为我们提供了对小细胞肺癌（SCLC）和非小细胞肺癌（NSCLC），包括腺癌（ADC）和鳞状细胞癌（SCC）之间遗传变异的新认识。使用生物信息学方法对肺癌亚型的基因组研究中的遗传变异进行了整合和进一步分析。肺癌亚型具有一些共同的遗传变异，如肿瘤抑制基因 TP53 的功能障碍，也具有其自身的特定变异，如 ADC 中的 MET、SCC 中的 FGFR1 和 FGFR3 以及 SCLC 中的 MYC。肺癌 ADC 和 SCC 中的激活途径主要集中在 MAPK 和 PI3K 上，每个途径分别具有不同的关键基因，而 SCLC 的激活途径主要集中在 JAK-STAT 途径上。还评估了基于这些遗传变异（如 SNP）的肺癌亚型的诊断。这些结果为不同肺癌亚型的不同发病机制提供了进一步的见解。
Zotero 插件